HOME >> MEDICINE >> NEWS
Mayo Clinic researchers discover how key cancer protein works

" (fos-for-a-LAY-shun) is required at certain cell-cycle stages to activate proteins associated with the BRCA1 gene. These proteins are essential to the effective tumor-suppression function that BRCA1 genes perform.

Biology Backgrounder

Genes are strings of DNA molecules. They are found on chromosomes within cell nuclei. DNA is like a storage bin for vital information -- like the hard drive of a computer. To be useful, a computer hard drives needs to run a program that performs work. It's the same with DNA. To be useful, it runs programs (RNAs) that make desired products. The products are proteins. Proteins are the substances that carry out all life functions, which is why advanced cancer research focuses on them.

To do their jobs, proteins need to be activated. They become activated by binding to other protein partners. The Mayo Clinic team investigated a specific kind of protein the BRCA1 gene codes for, known as a BRCT-domain protein. The BRCT-domain influences how the protein binds and with what protein partners it binds -- which in turn, affects the role the protein plays in the cycle of cell growth. BRCT domains are found in many proteins involved in cell-cycle regulation, and have for some years been thought to be key players in cell-cycle regulation. But just how they did so was not known.

The Mayo Clinic Research Solves The Mystery

The Mayo team showed that phosphorylation of a binding partner is necessary to activate the BRCT-domain protein. Once activated, the BRCT-domain protein then helps regulate vital tasks in the cell cycle. These tasks include repairing DNA or signaling DNA damage. When these tasks are accomplished, the BRCA1 gene can function correctly to suppress tumors. Without phosphorylation of BRCA1 binding partners, BRCA1 cannot function to suppress tumors. This leaves cells vulnerable to the cumulative mutations that can eventually produce breast cancer.

Implications for Pa
'"/>

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-2511
Mayo Clinic
23-Oct-2003


Page: 1 2 3

Related medicine news :

1. Mayo Clinic discovers new pathway against pancreatic cancer
2. Mayo Clinic develops first genomic-based test to predict stroke from ruptured brain aneurysm
3. Mayo Clinic study sets threshold for valve repair surgery
4. Mayo Clinic researcher calls for improved newborn screening
5. Mayo Clinic study finds obese kidney donors face few increased risks
6. Mayo Clinic identifies key cellular process in prostate and other cancers
7. Clinical breast examination offers modest benefit to breast cancer screening program
8. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
9. Clinicians report missing patient information is common
10. Mayo Clinic discovers a key to low metabolism and major factor in obesity
11. Clinical trial of Etanercept for Wegeners disease shows no benefit

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Mayo Clinic researchers discover how key cancer protein works

(Date:8/3/2015)... ... August 03, 2015 , ... Novation, ... Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can help ... , Annually, more than 8.6 million adverse drug events are reported in ...
(Date:8/3/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today welcomed the announcement by OPKO Health that the US Food and ... treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s ...
(Date:8/3/2015)... Los Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... emergency dental services to help patients in need. Most people know that general health ... hospital emergency. Unfortunately, a fewer amount of people know where to turn to during ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, ... contract lifecycle management solution, as well as announced the date of its next ... and ease of contract management tasks as well as enhancements to the customer ...
(Date:8/3/2015)... ... August 03, 2015 , ... Results ... Navigant Center for Healthcare Research and Policy Analysis show widespread support for the ... said they agreed or strongly agreed that the controversial law passed in 2010 ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3
(Date:8/3/2015)... August 3, 2015 /OFF ... Group LLC, PIV757417 The following release: "Biotech Advancements ... Drug Products & Treatments for Critical-Care Patients With ... time: 3 Aug 2015 12:30 GMT ... military surgical research and top-tier universities for identifying ...
(Date:8/3/2015)... Fla. , Aug. 3, 2015  Charleston ... initiation of its second clinical development program with ... candidate, CL-H1T.  CL-H1T contains fast-dissolving ... being developed as a treatment for migraine headache ... "Many patients with migraine headaches also ...
(Date:8/3/2015)... ZIONA, Israel , August 3, ... TASE: BVXV) today announced it received the statistical analysis of ... vaccine (M-001), administered in the BVX-005 phase II trial which ... future strains which did not exist at the time of ... (flu) strain that caused the epidemic in the ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
Cached News: